| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Product revenue | 1,862,050 | 2,892,635 | 4,473,792* | 1,696,050 |
| Cost of product revenue | 871,786 | 1,324,807 | 1,861,230* | 781,215 |
| Product gross profit | 990,264 | 1,567,828 | 2,612,562* | 914,835 |
| Collaborations revenue | NaN | NaN | 750,000* | NaN |
| Selling, general and administrative | 1,919,371 | 1,885,455 | -275,102.5* | 1,618,950 |
| Research and development | 1,468,090 | 1,389,680 | 943,640* | 1,182,485 |
| Total operating expenses | 3,387,461 | 3,275,135 | 668,537.5* | 2,801,435 |
| License revenue | NaN | NaN | NaN | 0 |
| Gain from operations | -2,397,197 | -1,707,307 | 2,694,024.5* | -1,886,600 |
| Fair value change in warrant liability | 8,271 | -222,740 | 280,294* | -319,625 |
| Financing costs | NaN | NaN | 306,088* | 9,325 |
| Other income | 23,446 | 46,677 | -55,804* | 75,432 |
| Gain before income taxes | -2,382,022 | -1,437,890 | 2,051,838.5 | -1,500,868 |
| Provision for income taxes | NaN | NaN | NaN | 0 |
| Net gain | -2,382,022 | -1,437,890 | 2,051,838.5 | -1,500,868 |
| Basic EPS | -0.28 | -0.03 | 0.051 | -0.03 |
| Diluted EPS | -0.28 | -0.03 | 0.051 | -0.03 |
| Basic Average Shares | 8,484,926 | 50,331,155 | 40,152,873* | 48,604,996 |
| Diluted Average Shares | 8,484,926 | 50,331,155 | 40,152,873* | 48,604,996 |
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)